valproic acid has been researched along with Diabetes Mellitus, Adult-Onset in 14 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this 5-year naturalistic study of patients treated with clozapine was to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors, including weight gain, lipid abnormalities, age, clozapine dose, and treatment with valproate." | 9.09 | Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. ( Cagliero, E; Goff, DC; Gray, C; Hayden, DL; Henderson, DC; Nasrallah, RA; Schoenfeld, DA, 2000) |
| "Valproic acid (VPA), as one of the most widely prescribed antiepileptic drugs (AED) for many types of epilepsy in adults and children, is associated with weight gain, alteration of adipocytokine homeostasis, insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD)." | 7.79 | The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? ( Ebenbichler, CF; Laimer, M; Luef, G; Rauchenzauner, M; Salzmann, K; Sandhofer, A; Sturm, W; Tschoner, A; Walser, G; Wiedmann, M, 2013) |
| "The goal of this 5-year naturalistic study of patients treated with clozapine was to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors, including weight gain, lipid abnormalities, age, clozapine dose, and treatment with valproate." | 5.09 | Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. ( Cagliero, E; Goff, DC; Gray, C; Hayden, DL; Henderson, DC; Nasrallah, RA; Schoenfeld, DA, 2000) |
| " We included patients who had a diagnosis of bipolar disorder and were prescribed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maintenance mood stabilizer treatment." | 3.83 | Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study. ( Geddes, JR; Hayes, JF; King, M; Marston, L; Osborn, DP; Walters, K, 2016) |
| "Valproic acid (VPA), as one of the most widely prescribed antiepileptic drugs (AED) for many types of epilepsy in adults and children, is associated with weight gain, alteration of adipocytokine homeostasis, insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD)." | 3.79 | The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? ( Ebenbichler, CF; Laimer, M; Luef, G; Rauchenzauner, M; Salzmann, K; Sandhofer, A; Sturm, W; Tschoner, A; Walser, G; Wiedmann, M, 2013) |
| "He was diagnosed with type 2 diabetes mellitus, started treatment with empagliflozin, and his body weight decreased gradually." | 1.56 | Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction. ( Miyauchi, T, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, JW | 1 |
| Young, JG | 1 |
| Sarvet, AL | 1 |
| Bailey, LC | 1 |
| Heerman, WJ | 1 |
| Janicke, DM | 1 |
| Lin, PD | 1 |
| Toh, S | 1 |
| Block, JP | 1 |
| Miyauchi, T | 1 |
| Axelsson, AS | 1 |
| Mahdi, T | 1 |
| Nenonen, HA | 1 |
| Singh, T | 1 |
| Hänzelmann, S | 1 |
| Wendt, A | 1 |
| Bagge, A | 1 |
| Reinbothe, TM | 1 |
| Millstein, J | 1 |
| Yang, X | 1 |
| Zhang, B | 1 |
| Gusmao, EG | 1 |
| Shu, L | 1 |
| Szabat, M | 1 |
| Tang, Y | 1 |
| Wang, J | 1 |
| Salö, S | 1 |
| Eliasson, L | 1 |
| Artner, I | 1 |
| Fex, M | 1 |
| Johnson, JD | 1 |
| Wollheim, CB | 1 |
| Derry, JMJ | 1 |
| Mecham, B | 1 |
| Spégel, P | 1 |
| Mulder, H | 1 |
| Costa, IG | 1 |
| Zhang, E | 1 |
| Rosengren, AH | 1 |
| Patel, MM | 1 |
| Patel, BM | 2 |
| Raghunathan, S | 1 |
| Porwal, U | 1 |
| Huang, S | 1 |
| Zhu, M | 1 |
| Wu, W | 1 |
| Rashid, A | 1 |
| Liang, Y | 1 |
| Hou, L | 1 |
| Ning, Q | 1 |
| Luo, X | 1 |
| Khan, S | 1 |
| Kumar, S | 1 |
| Jena, G | 1 |
| Hayes, JF | 1 |
| Marston, L | 1 |
| Walters, K | 1 |
| Geddes, JR | 1 |
| King, M | 1 |
| Osborn, DP | 1 |
| Agrawal, RP | 1 |
| Goswami, J | 1 |
| Jain, S | 1 |
| Kochar, DK | 2 |
| Noh, H | 1 |
| Oh, EY | 1 |
| Seo, JY | 1 |
| Yu, MR | 1 |
| Kim, YO | 1 |
| Ha, H | 1 |
| Lee, HB | 1 |
| Hansen, N | 1 |
| Beck, M | 1 |
| Leykamm, S | 1 |
| Kleinschnitz, C | 1 |
| Rauchenzauner, M | 1 |
| Laimer, M | 1 |
| Wiedmann, M | 1 |
| Tschoner, A | 1 |
| Salzmann, K | 1 |
| Sturm, W | 1 |
| Sandhofer, A | 1 |
| Walser, G | 1 |
| Luef, G | 1 |
| Ebenbichler, CF | 1 |
| Jain, N | 1 |
| Agarwal, RP | 1 |
| Srivastava, T | 1 |
| Agarwal, P | 1 |
| Gupta, S | 1 |
| Henderson, DC | 1 |
| Cagliero, E | 1 |
| Gray, C | 1 |
| Nasrallah, RA | 1 |
| Hayden, DL | 1 |
| Schoenfeld, DA | 1 |
| Goff, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350] | Phase 4 | 20 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | Units/mL per 10 minutes (Mean) |
|---|---|
| Rosiglitazone | -151 |
| Placebo | 19 |
Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8
| Intervention | microUnits/mL (Mean) |
|---|---|
| Rosiglitazone | 3.2 |
| Placebo | 0.4 |
Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Rosiglitazone | .002 |
| Placebo | -0.01 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
1 review available for valproic acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
[Arm and blood glucose out of control].
Topics: Aged; Brain; Diabetes Mellitus, Type 2; Diagnosis, Differential; Dyskinesias; GABA Agents; Humans; H | 2009 |
3 trials available for valproic acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective double-blind randomized placebo-controlled study.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Diabetic Neuropathies; | 2009 |
Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study.
Topics: Adult; Aged; Anticonvulsants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; | 2002 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
10 other studies available for valproic acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Comparison of Rates of Type 2 Diabetes in Adults and Children Treated With Anticonvulsant Mood Stabilizers.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Cohort Studies; Diabetes Mellitus, T | 2022 |
Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction.
Topics: Aged; Antimanic Agents; Benzhydryl Compounds; Bipolar Disorder; Diabetes Mellitus, Type 2; Drug Inte | 2020 |
Sox5 regulates beta-cell phenotype and is reduced in type 2 diabetes.
Topics: Animals; Calcium; Calcium Channels; Chromatin; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2017 |
Repurposing of sodium valproate in colon cancer associated with diabetes mellitus: Role of HDAC inhibition.
Topics: Animals; Anticonvulsants; Blood Glucose; Carcinoembryonic Antigen; Cell Line, Tumor; Colon; Colonic | 2018 |
Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Experimen | 2014 |
Valproate pretreatment protects pancreatic β-cells from palmitate-induced ER stress and apoptosis by inhibiting glycogen synthase kinase-3β.
Topics: Activating Transcription Factor 4; Animals; Apoptosis; Cell Survival; Diabetes Mellitus, Type 2; End | 2014 |
Valproic acid reduces insulin-resistance, fat deposition and FOXO1-mediated gluconeogenesis in type-2 diabetic rat.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gluconeogenesis; Insulin Resist | 2016 |
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cardiovascular Diseases; Chemical an | 2016 |
Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Topics: Acetylcysteine; Amides; Animals; Antioxidants; Biphenyl Compounds; Cell Line; Cell Transdifferentiat | 2009 |
The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep?
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Diabetes Mellitus, Type 2; Fatty Liver; Female; Glu | 2013 |